Markets:

Overview

News

Currencies

International

Treasuries

Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

111.03 +0.99 (+0.90%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rhythm Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Peering Into Rhythm Pharmaceuticals's Recent Short Interest ↗

September 11, 2025

Via Benzinga

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

August 27, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

August 20, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

12 Analysts Have This To Say About Rhythm Pharmaceuticals ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years ↗

June 05, 2025

Via Benzinga

Rhythm (RYTM) Q2 Revenue Jumps 67% ↗

August 05, 2025

Via The Motley Fool

Topics Intellectual Property

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Reports Mixed Q2 2025 Earnings: Revenue Beat Overshadowed by Wider Losses ↗

August 05, 2025

Rhythm Pharmaceuticals Q2 2025 results show revenue beat but EPS miss, causing a 5.7% pre-market drop. Regulatory progress for setmelanotide remains on track.

Via Chartmill

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

August 05, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

July 22, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Should You Invest in This Under-the-Radar Weight Loss Stock? ↗

July 21, 2025

Via The Motley Fool

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 10 Analysts ↗

July 18, 2025

Via Benzinga

Rhythm Pharmaceuticals CFO Sells 42,120 Shares ↗

July 18, 2025

Via The Motley Fool

Topics Regulatory Compliance

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

July 12, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

July 10, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Rhythm Pharma Gets Price-Target Bump Ups To $129 After Oral Obesity Drug Impresses In Phase 2; Retail Appetite Swells ↗

July 10, 2025

Analysts from Wells Fargo, Stifel, and others raised their targets following the release of strong BMI reduction data for bivamelagon.

Via Stocktwits

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

July 09, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

July 09, 2025

Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise ↗

July 09, 2025

Rhythm's bivamelagon cut BMI and hunger scores in Phase 2 trial for hypothalamic obesity, prompting plans to discuss Phase 3 with regulators.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 09, 2025

Via Benzinga

These stocks are moving in today's session ↗

July 09, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity ↗

July 09, 2025

Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity.

Via Stocktwits

Topics Government

Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity ↗

July 09, 2025

Rhythm Pharmaceuticals shares surged to a record high Wednesday on promising results for a drug that could treat obesity.

Via Investor's Business Daily

Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday ↗

July 09, 2025

Via Benzinga

Which stocks are gapping on Wednesday? ↗

July 09, 2025

The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

July 09, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

Wondering what's happening in today's after-hours session? ↗

July 08, 2025

As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

July 08, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

8 Analysts Have This To Say About Rhythm Pharmaceuticals ↗

June 26, 2025

Via Benzinga

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

June 25, 2025

From Rhythm Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.